PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 1730 (117th)

Speeding Therapy Access Today Act of 2021

referredUnited States· United States Congress· EN

Introduced

10 March 2021

Last action

10 March 2021 · Introduced

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. Bilirakis, Gus M. [R-FL-12], G. K. Butterfield, Darren Soto, ALCEE HASTINGS, Jefferson Van Drew, Mike Levin, John Joyce, Rodney Davis, Rep. Tenney, Claudia [R-NY-24], Rep. Lee, Susie [D-NV-3], Susan Wild, Rep. Fitzpatrick, Brian K. [R-PA-1], Antonio Delgado, Debbie Lesko, Grace Napolitano, Chris Jacobs, Tom Cole, Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Kelly, Mike [R-PA-16], Rep. Ross, Deborah K. [D-NC-2], Rep. Kustoff, David [R-TN-8], Rep. Gottheimer, Josh [D-NJ-5], Jared Huffman, Rep. DeSaulnier, Mark [D-CA-10], Rep. Lynch, Stephen F. [D-MA-8], Dean Phillips, Rep. Neguse, Joe [D-CO-2], Jenniffer González-Colón, John Yarmuth, Rep. Dean, Madeleine [D-PA-4], Sanford Bishop, Cynthia Axne, Eric Swalwell, Rep. Stansbury, Melanie A. [D-NM-1], Tom O'Halleran, Rep. Wilson, Joe [R-SC-2], Rep. Crow, Jason [D-CO-6], J. Hill, Rep. Matsui, Doris O. [D-CA-7], Markwayne Mullin, Don Bacon

Subjects

Healthcare

Source updated

5 December 2025

Healthcare

Summary

Speeding Therapy Access Today Act of 2021 This bill requires and authorizes various actions to accelerate the development of therapies for rare diseases. The Food and Drug Administration (FDA) shall establish the Intercenter Institute on Rare Diseases and Conditions. The institute shall (1) coordinate engagement with relevant stakeholders, (2) build the FDA's expertise in the review of medical products to treat rare diseases, (3) coordinate regulatory science initiatives related to rare diseases, (4) establish and implement a program to make recommendations to address challenges associated with developing medical products to treat rare diseases in an individual or in very small populations, (5) convene a stakeholder meeting to consider potential amendments to labels for medical products to treat rare diseases, and (6) establish and carry out a program to facilitate voluntary communication between the sponsors of such medical products and third-party payers (e.g., insurance companies). The bill also authorizes the FDA to make grants to assist in developing practices related to the development and production of individualized therapies or therapies to treat very small populations. The bill also establishes an advisory committee to advise the FDA on issues related to the development of therapies to treat rare diseases.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 10 March 2021

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

  2. 10 March 2021

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  3. 10 March 2021

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 10 March 2021

    Introduced

    Introduced in House

    Source: IntroReferral

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.